Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
Affiliations : Duke Clinical Research Institute, Durham, NC, USA.
Journal : Am. Heart J. (2010)
Related Links: Pubmed | Publisher website
Display Ads on JAFIB to reach Users world wide...
Suggest an Event to get good mileage from Users World wide...